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Background: Dengue virus, which belongs to the Flavivirus 
genus of the Flaviviridae family, causes fatal dengue hemor-
rhagic fever (DHF) and dengue shock syndrome (DSS) with 
infection risk of 2.5 billion people worldwide. However, ap-
proved vaccines are still not available. Here, we explored the 
immune responses induced by alternating prime-boost vacci-
nation using DNA vaccine, adenovirus, and vaccinia virus ex-
pressing E protein of dengue virus type 2 (DenV2). Methods: 
Following immunization with DNA vaccine (pDE), adenovirus 
(rAd-E), and/or vaccinia virus (VV-E) expressing E protein, E 
protein-specific IgG and its isotypes were determined by 
conventional ELISA. Intracellular CD154 and cytokine stain-
ing was used for enumerating CD4＋ T cells specific for E 
protein. E protein-specific CD8＋  T cell responses were eval-
uated by in vivo CTL killing activity and intracellular IFN-γ 
staining. Results: Among three constructs, VV-E induced the 
most potent IgG responses, Th1-type cytokine production by 
stimulated CD4＋ T cells, and the CD8＋ T cell response. 
Furthermore, when the three constructs were used for alter-
nating prime-boost vaccination, the results revealed a differ-
ent pattern of CD4＋  and CD8＋  T cell responses. i) Priming 
with VV-E induced higher E-specific IgG level but it was de-
creased rapidly. ii) Strong CD8＋ T cell responses specific 
for E protein were induced when VV-E was used for the pri-
ming step, and such CD8＋ T cell responses were sig-
nificantly boosted with pDE. iii) Priming with rAd-E induced 
stronger CD4＋  T cell responses which subsequently boost-
ed with pDE to a greater extent than VV-E and rAd-E. 
Conclusion: These results indicate that priming with live viral 
vector vaccines could induce different patterns of E pro-
tein-specific CD4＋  and CD8＋  T cell responses which were 
significantly enhanced by booster vaccination with the DNA 
vaccine. Therefore, our observation will provide valuable in-
formation for the establishment of optimal prime-boost vac-
cination against DenV. 
[Immune Network 2011;11(5):268-280]
INTRODUCTION
Dengue  virus  (DenV)  has  four  serotypes  (DenV1,  DenV2, 
DenV3, and DenV4), and belongs to the Flavivirus genus of 
the Flaviviridae family transmitted to humans by the mosquito 
Aedes aegypti (1-3). DenV poses a significant public health 
threat  to  2.5  billion  people  at  the  risk  of  infection  (1-3). 
Around 100 million cases of DenV infections occur annually, 
producing symptoms ranging from mild fever to severe hem-
orrhagic, potentially fatal fever (1-3). Dengue hemorrhagic fe-
ver  (DHF)  and  dengue  shock  syndrome  (DSS),  which  re-
portedly affect about 500,000 people per year, are potentially 
fatal diseases (1-3). These diseases are spreading from trop-
ical to subtropical areas of the world by global warming, in-
creasing travel activity, and uncontrolled urbanization (1-3). 
Despite global morbidity and mortality, the pathogenesis of 
diseases  caused  by  DenV  infection  is  poorly  understood. 
Even though several factors such as viral virulence, age and 
genetic predisposition of the patient are implicated, the most 
important factor is considered to be sequential infection by 
different serotypes in an endemic area (4,5). While approved 
vaccines remain unavailable, several approaches to develop 
a dengue vaccine have been evaluated. These include the tra-Immunity Induced by Alternating Prime-boost Vaccination against DenV2
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ditional  live  attenuated  vaccines  (6-9),  recombinant  subunit 
vaccines  produced  using  several  different  host  systems 
(10-13),  chimeric  virus  such  as  yellow  fever  vaccine  vector 
YF17D-based  ChimeriVax  (14,15)  and  RepliVax  (16),  and 
DNA  vaccine  (17,18). 
    All four dengue serotypes have co-circulated in most en-
demic countries at various times, thereby causing concurrent 
and/or  sequential  infection  by  multiple  serotypes  (19). 
Furthermore,  there  is  the  potential  for  antibody-dependent 
enhancement  (ADE)  associated  with  non-neutralizing  cross- 
reactive  antibodies  arising  from  immunization  with  mono-
valent dengue virus vaccines (19). Therefore, a dengue virus 
vaccine should elicit protective immunity simultaneously to all 
four serotypes. The current approach to making a tetravalent 
dengue vaccine is to create monovalent vaccine candidates, 
and  then  mix  these  to  obtain  a  tetravalent  formulation 
(20-22). The application of this approach to live, replicating 
virus vaccine has revealed the potential for viral interference 
in  some  instances  (22,23).  Considering  viral  interference  in 
vaccination  with  live  viral  vector  vaccine,  multiple  prime- 
boost  vaccinations  with  alternating  vaccine  vehicles  using 
DNA  vaccine  expressing  the  same  antigen  may  become  an 
effective strategy for eliciting robust immune responses to the 
t a r g e t  a n t i g e n  ( 2 4 ) .  N o t a b l y ,  t h e  p r i m e - b o o s t  p r o t o c o l ,  i n  
w h i c h  a n t i g e n - e n c o d i n g  D N A  v a c c i n e  i s  a d m i n i s t e r e d  f i r s t ,  
followed by a boost with live viral vector expressing the same 
antigen,  has  elicited  effective  protective  immunity  in  both 
mouse  and  primate  models  of  several  infectious  diseases 
(25,26).  However,  some  experiments  claimed  that  priming 
with live viral vector vaccine and boosting with DNA vaccine 
induces superior immune responses against encoded antigens 
(27,28), which suggest that optimal prime-boost protocol to 
induce effective immunity may be dependent on several fac-
tors such as encoded antigens, animal species, and properties 
of  vaccine  vectors.
    Various  viral  vectors  expressing  foreign  antigen,  such  as 
vaccinia  virus,  adenovirus  or  Fowlpox  have  been  used  for 
prime-boost  vaccination.  DNA-  and  vaccinia-based  vaccines 
for a pre-erythrocytic malaria antigen that were delivered in 
a  prime-boost  protocol  induced  5-  to  10-fold  greater  T-cell 
responses  than  each  vaccine  alone  (29).  In  addition,  gene- 
based  vectors,  such  as  replication-incompetent  adenovirus, 
have proven particularly effective in eliciting enhanced cellular 
and  humoral  immunities  compared  to  either  agent  alone 
(30,31). Replication-incompetent adenovirus has the ability to 
efficiently deliver antigens and express them at high levels in 
a variety of cells, making them ideal vaccine carriers (32,33). 
In contrast, vaccinia virus-vectored recombinants show unre-
stricted replication in immune-compromised individuals (34). 
Here, we explored the immune responses induced by alter-
nating prime-boost vaccination using these different viral vec-
tor vaccines expressing E protein of DenV2, which is a major 
immunogen  involved  in  conferring  protective  immunity 
against  dengue  infection.  We  found  that  vaccinia  virus  ex-
pressing  E  protein  produced  better  responses  compared  to 
adenovirus at equivalent antigen doses, and these viral vec-
tors elicited different patterns of CD4＋ and CD8＋ T cell re-
sponses against E protein when used for alternating prime- 
boost  vaccination.  Therefore,  humoral  and  cellular  immune 
responses induced by alternating prime-boost vaccination us-
ing  live  viral  vector  vaccine,  vaccinia  and  adenovirus,  and 
DNA  vaccine  are  discussed.
MATERIALS AND METHODS
Animals and ethics statement
Female BALB/c (H-2
d) mice, 5 to 6 weeks of age, were pur-
chased from Samtako (Osan, Korea). The mice were main-
tained in the animal facility at Chonbuk National University 
under standard conditions. All experimental procedures and 
animal management procedures were undertaken in accord-
ance  with  the  requirement  of  the  Animal  Care  and  Ethics 
Committees of Chonbuk National University. The animal fa-
cility at Chonbuk National University is fully accredited by the 
National  Association  of  Laboratory  Animal  Care.
Plasmid DNA preparation
Plasmid  DNA  encoding  E  protein  of  dengue  virus  type  2 
(DenV2) under the control of the cytomegalovirus (CMV) pro-
moter (pDE) was constructed by inserting cDNA of the E pro-
tein gene into pCI-neo vector (Promega, Madison, WI). For 
immunization,  plasmid  DNA  was  purified  by  polyethylene 
glycol  (PEG)  precipitation  as  described  previously  (35). 
Briefly, cellular proteins were precipitated with one volume 
of 7.5 M ammonium acetate followed by isopropanol precip-
itation of the supernatant. After PEG precipitation, the plas-
mid  was  extracted  three  times  with  phenol-chloroform  and 
precipitated with pure ethanol. The DNA quality was checked 
by electrophoresis on a 1% agarose gel. The plasmid DN A 
concentration  was  measured  using  a  NanoDrop  2000  spec-
trophotometer  (Thermo  Fisher  Scientitific,  Pittsburgh,  PA). 
The  amount  of  endotoxin  was  determined  by  the  Limulus Immunity Induced by Alternating Prime-boost Vaccination against DenV2
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amebocyte lysate (LAL) test (＜0.05 EU/μg). The in vivo ef-
fect of endotoxin and CpG was addressed by parallel admin-
istration  of  the  control  vector,  pCI-neo.
Construction of recombinant adenovirus expressing 
E protein
The E1- and E3-deleted expression vector into which E pro-
tein of DenV2 is cloned was used to construct replication-in-
competent  adenovirus  expressing  E  protein  of  DenV2  (36). 
E  p r o t e i n  o f  D e n V 2  w a s  e x p r e s s e d  i n  t h e  r e p l i c a t i o n - i n -
competent adenovirus by cloning E protein gene under the 
control of the human CMV promoter. We initially constructed 
recombinant entry vector pENTR11 (Invitrogen, Carlsbad, CA) 
containing  E  protein  gene  by  RT-PCR  amplification  and 
subcloning.  Using  LR  Clonase  (Invitrogen)  for catalysis,  the 
recombinant entry vector pENTR11 containing E protein gene 
were mixed with adenoviral destination vector, pAd/CMV/V5- 
DEST (Invitrogen), to generate recombinant adenoviral plas-
mid  containing  E  protein  gene.  After  transforming  the  re-
combinant adenoviral plasmid DNA into competent  E.  coli, 
we extracted and purified DNA from selected putative pos-
itive  clones  identified  by  PCR  amplification  and  gel  elec-
trophoresis. Those putative clones were also cultured on LB 
plates  containing  30μg/ml  chloramphenicol,  since  true  ex-
pression  clones  would  be  ampicillin-resistant  and  chlor-
amphenicol-sensitive. Following digestion of the recombinant 
adenoviral plasmid DNA containing E protein gene with the 
restriction enzyme PacI, human embryonic kidney 293A cells 
were  transfected  to  generate  replication-incompetent  aden-
ovirus.  Culture  medium  was  replaced  with  fresh  complete 
culture medium every 2∼3 days until visible regions of the 
cytopathic effect (CPE) were observed. When approximately 
50∼70% CPE was observed, adenovirus-containing cells and 
media were harvested. The expression of E protein was iden-
tified  with  RT-PCR  after  NIH3T3  cells  were  infected  with 
rAd-E. The replication-incompetent adenovirus expressing E 
protein  of  DenV2  (rAd-E)  were  purified  with  the  Adeno-X 
mini purification kit (Clontech, Mountain View, CA), titrated 
by  plaque  assay,  and  stored  at  −80
oC  until  use. 
Construction of vaccinia virus expressing E protein
Recombinant  vaccinia  virus  expressing  E  protein  of 
DenV2 (VV-E) was constructed using the shuttle vector, 
p S C 1 1  ( p r o v i d e d  b y  Dr .  B .  Mo s s ,  N I H,  B e t h e s d a ,  MD)  
(37). Plasmid pSC11 encoding E protein gene was subcl-
oned from pGEMT/E vector by restricting the plasmid us-
ing  BglII  and  Sca  I  endonucleases.  Human  thymidine 
kinase-deficient  143B  cell  (HuTK-  cells)  were  grown  to 
80%  confluency  in  Eagle’s  Minimum  Essential  Medium 
(EMEM) containing 5% FBS. They were infected with vacci-
nia virus strain WR at a multiplicity of infection (MOI) of 0.05 
followed by transfection with pSC11 encoding E protein gene 
using  Lipofectamine  (Gibco-BRL,  Grand  Island,  NY).  After 
CPE had developed (usually in 48∼72 h), the cells were rup-
tured and the cell lysates containing the putative recombinant 
virions were employed to plaque isolation in the presence of 
bromodeoxyuridine  (BrdU;  25μg/ml)  and  Bluo-gal  (0.6 
mg/ml;  Gibco-BRL).  Blue  plaques,  produced  by  replicating 
recombinant virion expressing the lacZ gene, were collected 
and used to enhance the virus content of the plaques by in-
oculating a confluent layer of HuTK- cells. Recombinant vac-
c i n i a  v i r u s  e x p r e s s i n g  E  p r o t e i n  o f  D e n V 2  w e r e  h a r v e s t e d ,  
plaques  purified  and  enhanced  by  infecting  larger  volumes 
of two or more cell monolayers. The expression of E protein 
by recombinant vaccinia virus was confirmed by immunoblot. 
The titers of recombinant vaccinia virus were determined by 
p l a q u e  a s s a y  a n d  s t o r e d  a t  −80
oC  until  needed. 
Protocol for vaccination and sample collection
Groups of mice (5- to 6-weeks old female) were immunized 
with either 100μg of pDE or 10
6 PFU of rAd-E and VV-E via 
the  intramuscular  (i.m.)  route.  In  prime-boost  experiments, 
primarily immunized mice were boosted 7 days later with al-
ternative vaccine vehicle via the same route. The i.m. immuni-
zation was performed by injecting the indicated immunogen 
into the anterior tibialis muscle. Control mice were given the 
empty  vector  (pCI-neo),  replication-incompetent  adenovirus 
expressing the LacZ gene (rAd-LacZ), and vaccinia virus ex-
pressing chicken ovalbumin (VV-OVA). Serum samples were 
collected by retro-orbital bleeding and stored at −80
oC until 
needed.
ELISA for E specific antibody, IgG, IgG1, and IgG2a
A standard enzyme-linked immunosorbent assay (ELISA) was 
used to determine the levels of E-specific antibodies in the 
serum samples. Briefly, ELISA plates were coated overnight 
at 4
oC with E protein (100 ng/well) in the sample wells and 
goat  anti-mouse  IgG/IgG1/IgG2 a  ( S o u t h e r n  B i o t e c h n o l o g y  
Associate Inc., Birmingham, AL) in standard wells. E protein 
o f  D e n V 2  w a s  p u r i f i e d  from  recombinant  E.  coli b y  t h e  
Ni-NTA His-Tag column (Peptron Co. Ltd, Daejeon, Korea). 
The  plates  were  washed  three  times  with  PBS-Tween  20 Immunity Induced by Alternating Prime-boost Vaccination against DenV2
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(PBST) and blocked with 2% non-fat dehydrated milk. The 
samples were serially diluted  2-fold,  and incubated for 2 h 
at  37
oC.  This  was  followed  by  incubation  with  horseradish 
peroxidase-conjugated goat anti-mouse IgG/IgG1/IgG2a for 1 
h. The color was developed by the addition of a suitable sub-
strate (11 mg of 2,2-azinobis-3-ethylbenzothiazoline-6-sulfonic 
acid in a mixture of 25 ml of 0.1 M citric acid, 25 ml of 0.1 
M sodium phosphate, and 10μl of hydrogen peroxide). The 
concentration of E-specific antibodies was determined using 
an automated ELISA reader and the SOFTmax Pro4.3 program 
(Spectra  MAX340:  Molecular  Device,  Sunnyvale,  CA).
Cytokine ELISA following in vitro stimulation of CD4＋ 
T cells
To  examine  cytokine  production  from  stimulated  CD4＋ T 
cells, splenocytes prepared from immunized mice were used 
as  responder  cells.  The  syngeneic  antigen-presenting  cell 
(APC)  populations  enriched  by  OptiPrep
TM  gradient  (13.8% 
iodixanol; Axis-Shield, Oslo, Norway) (38) were pulsed with 
E protein (100μg/ml) and subsequently used as stimulators. 
The  responder  and  E  protein-pulsed  stimulator  cells  were 
combined  at  responder-to-stimulator  ratios  of  5：1,  2.5：1, 
and 1.25：1 in 200μl of RPMI medium. The culture super-
natants were harvested after 3 days of incubation. A similar 
number of responder cells were stimulated with 5μg of con-
canavalin  A  for  48  h  as  a  polyclonal  positive  stimulator.
    ELISA was used to determine cytokine levels of IL-2, IL-4, 
and IFN-γ in the culture supernatants. Briefly, 100 ng per 
well of either IL-2, IL-4, or IFN-γ anti-mouse antibody (eBio-
science,  San  Diego,  CA;  clone  no.  JES6-1A12,  11B11,  and 
R4-6A2,  respectively)  was  added  to  each  ELISA  plate.  The 
plates were then incubated overnight at 4
oC and then washed 
three  times  with  PBS-Tween  20.  Next,  they  were  blocked 
with 3% non-fat dried milk for 2 h at 37
oC. The culture super-
natant and recombinant IL-2, IL-4, and IFN-γ protein (Phar-
mingen,  San  Diego,  CA)  as  standards  were  used.  Each  of 
these reagents was serially diluted two-fold, and then added 
to the corresponding plates. The plates were then incubated 
overnight at 4
oC. Next, biotinylated IL-2, IL-4, and IFN-γ an-
tibodies (eBioscience; clone no. JES6-5H4, BVD6-24G2, and 
XMG1.2,  respectively)  were  added,  after  which  the  plates 
were incubated at 37
oC for an additional 2 h. The plates were 
then washed and incubated with peroxidase-conjugated strep-
tavidin (Pharmingen) for 1 h, after which the color was devel-
oped  with  the  addition  of  a  substrate  (2,2-azinobis-3-ethyl-
benzothiazoline-6-sulfonic acid) solution. The concentrations 
of cytokines were then determined using an automated ELISA 
reader  and  the  SOFTmax  Pro4.3  program  to  compare  the 
samples to two concentrations of standard cytokine protein. 
Data  were  expressed  by  subtracting  the  produced  cytokine 
levels  of  no  E  protein-treated  cultures  from  cytokine  pro-
duced  from  E  protein-stimulated  cultures.
Intracellular CD154 staining for E-specific CD4＋ T 
cells
W e  u s e d  i n t r a c e l l u l a r  C D 1 5 4  s t a i n i n g  t o  i d e n t i f y  E  p r o -
tein-specific CD4＋ T cells, as previously described (39,40). 
Briefly,  10
6 f r e s h l y  e x p l a n t e d  s p l e n o c y t e s  p e r  w e l l  w e r e  
stimulated  with  E  protein  (100μg/ml)  in  U-bottom  96-well 
plates for 12 h. Brefeldin A (2μg/ml) was added for the last 
6 h culture period to facilitate intracellular CD154 accumul-
ation.  After 12  h-stimulation, c e lls  we re  w as he d  tw ic e  w it h 
PBS containing 1% BSA, 0.05% NaN3, and 2μg/ml brefeldin 
A. Cells were subsequently incubated with FITC-conjugated 
anti-CD4 for surface staining, followed by fixation with PBS 
containing 10% formaldehyde. The surface-stained cells were 
then permeabilized, washed, and stained intracellularly by in-
cubation with PE-conjugated anti-CD154 for 30 min at room 
temperature.  After  several  washes,  the  intracellular  CD154 
molecules  were  determined  by  flow  cytometry.
In vivo CTL killing activity
An in vivo CTL assay was conducted as reported elsewhere 
(41). Splenocytes were collected from recipient mice 24 h af-
ter  adoptive  transfer  of  target c e l l s  t h a t  w e r e  p r e v i o u s l y  
pulsed with E331-339 (H-2L
d; SPCKIPFEI) eptiope peptide (1μg/ 
ml) and labeled with CFSE (2.5μM), and then analyzed by 
flow cytometry. To control for antigen specificity, unpulsed 
syngeneic splenocytes previously labeled with CFSE (0.25μM) 
were injected intravenously (i.v.) along with target cells. Each 
population was distinguished by their respective fluorescence 
intensity. The percentage of killing of target cells in immu-
nized mice was calculated using the following equation: ratio 
=  (percentage  of  CFSE
low/percentage  of  CFSE
high) .  T h e  p e r -
centage of specific lysis = (1 − [ratio of naïve/ratio of immu-
nized])/100.
Intracellular IFN-γ staining for E331-339-specific CD8＋ 
T cells
Single-cell  suspension  (5×10
6  cells/ml)  of  splenocytes  iso-
lated  from  immunized  mice  was  incubated  with  E331-339 
(H-2L
d; SPCKIPFEI) epitope peptide (2μg/ml) in RPMI media Immunity Induced by Alternating Prime-boost Vaccination against DenV2
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Figure 1. Serum IgG and its isotypes 
specific for E protein of DenV following
immunization with plasmid DNA and 
live viral vectors. Groups of mice were
immunized with plasmid DNA (pDE), 
recombinant adenovirus (rAd-E), and 
vaccinia virus (VV-E) expressing E 
protein. The levels of E-specific IgG (A),
IgG1 (B), IgG2a (C), and ratio of 
IgG2a/IgG1 (D) were determined by 
conventional ELISA 10 days post- 
immunization. Plasmid DNA empty 
vector (pCIneo), recombinant adeno-
virus expressing LacZ (rAd-LacZ), and 
vaccinia virus expressing OVA (VV- 
OVA) were used as the negative con-
trol. Data represent the average and 
standard deviation derived from 5 mice
per group. *p＜0.05; **p＜0.01 com-
pared between the indicated groups.
supplemented  with  10%  FBS,  2  mM  L-glutamine,  100  U/ml 
penicillin, and 100μg/ml streptomycin at 37
oC. After 6 h-in-
cubation, the stimulated splenocytes were employed to stain 
surface  CD8  followed  by  staining  intracellular  IFN-γ.  The 
IFN-γ-producing  CD8＋ T  cells  was  determined  by  flow 
cytometry.
Statistical analysis
Data are expressed as the average±standard deviation (SD) 
of the individual results. Where specified, the data were ana-
lyzed for statistical significance using an unpaired two-tailed 
Student t test. A value of p＜0.05 was considered statistically 
significant.
RESULTS
Humoral immune responses induced by plasmid 
DNA and live viral vectors expressing E protein
To evaluate the immune responses induced by plasmid DNA 
(pDE),  recombinant  adenovirus  (rAd-E)  and  vaccinia  virus 
(VV-E) expressing E protein of DenV2, groups of mice were 
immunized with these constructs and the levels of E-specific 
IgG in sera were determined 10 days post-immunization. pDE 
was observed to induce lower levels of E-specific IgG, when 
compared to live viral vectors (Fig. 1A). VV-E induced sig-
nificantly  higher  levels  of  E-specific  IgG  than  rAd-E  at  the 
equivalent amount of immunogens (10
6 PFU/mouse). When 
the distribution of E-specific IgG isotypes, IgG1 and IgG2a, 
was  evaluated,  VV-E  showed  significantly  higher  levels  of 
E-specific IgG1 and IgG2a, compared to pDE and rAd-E (Fig. 
1B and C). However, three constructs expressing E protein 
of DenV2 showed comparable ratios of IgG2a to IgG1 each 
other (Fig. 1D). These results indicate that constructed pDE, 
rAd-E and VV-E could successfully induce humoral responses 
s p e c i f i c  f o r  E  p r o t e i n  o f  D e n V 2 .
CD4＋ T cell responses induced by plasmid DNA 
and live viral vectors expressing E protein
After immunizing mice with pDE, rAd-E and VV-E, the cytokine 
production from CD4＋ T cells in response to E protein stim-
ulation was determined 14 days post-immunization. CD4＋ T 
cells prepared from VV-E immunized mice produced higher 
amounts of IL-2 and IFN -γ in  r es po ns e to  E  p ro te in  s ti m-
ulation, compared to those isolated from mice immunized by 
either pDE or rAd-E (Fig. 2 A∼C). In contrast, immunization 
with rAd-E exhibited a significantly higher production of IL-4 
compared to other forms of immunization (Fig. 2B). To un-
derstand immune responses induced by pDE, rAd-E or VV-E 
in detail, we determined the number of CD4＋ T cells specific 
for  E  protein  using  intracellular  CD154  staining  (39,40).  In Immunity Induced by Alternating Prime-boost Vaccination against DenV2
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Figure 2. Evaluation of CD4＋ T cell responses 
specific for E protein of DenV following immu-
nization with plasmid DNA and live viral vectors.
Two weeks after immunization with plasmid DNA
(pDE), recombinant adenovirus (rAd-E) and vac-
cinia virus (VV-E) expressing E protein of DenV,
splenocytes prepared from immunized mice were
stimulated with E protein-pulsed syngeneic APCs 
for 3 days. The levels of IL-2 (A), IL-4 (B), and IFN-
γ (C) in culture supernatants were determined by
ELISA. Plasmid DNA empty vector (pCIneo), re-
combinant adenovirus expressing LacZ (rAd- 
LacZ), and vaccinia virus expressing OVA (VV- 
OVA) were used as the negative control. (D) The
percentage of CD4＋ T cells responded by E pro-
tein stimulation was determined by intracellular 
CD154 staining assay. Data represent average and
standard deviation derived 4 mice per group. *p
＜0.05; **p＜0.01 compared between the in-
dicated groups.
consistent, VV-E immunization showed higher percentages of 
CD154＋CD4＋ T cells in response to E protein stimulation 
(Fig. 2D). Therefore, this result indicates that plasmid DNA 
and live viral vectors expressing E protein induced CD4＋ T 
cell responses and VV-E immunization induced the most po-
tent  immune  responses.
CD8＋ T cell responses induced by plasmid DNA 
and live viral vectors expressing E protein
To better understand immune responses induced by plasmid 
DNA,  live  viral  vectors  expressing  E  protein  of  DenV2,  we 
examined the in vivo CTL killing activity specific for E331-339 
(SPCKIPFEI)  epitope.  Similarly,  immunization  with  VV-E 
s h o w e d  t h e  m o s t  p o t e n t  a c t i v i t y  o f  in  vivo CTL ,  co m par ed 
to other types of immunization (Fig. 3A). When the percent-
age of IFN-γ-producing CD8＋ T cells in response to E331-339 
(SPCKIPFEI) epitope stimulation was determined, mice immu-
nized  with  VV-E  displayed  a  higher  percentage  of  IFN-γ- 
producing CD8＋ T cells than others (Fig. 3B). In line with 
antibody and CD4＋ T cell responses, this result indicates that 
VV-E  immunization  could  induce  more  potent  immune  re-
sponses  than  pDE  and  rAd-E.
Humoral immune responses induced by alternating 
prime-boost immunization using plasmid DNA and 
live viral vectors expressing E protein
To compare E-specific immune responses induced by alter-
nating prime-boost immunization with pDE, rAd-E, and VV-E, 
we first assessed the humoral responses following immuniza-
tion with the indicated protocols (Fig. 4A). The primary im-
munization with vaccinia virus expressing E protein followed 
by  boosting  with  adenovirus  expressing  E  protein  showed 
highest levels of E-specific IgG, but E-specific IgG lasted for 
14 days post-boosting with higher levels in the group that re-
ceived priming with rAd-E and boosting with VV-E. In gen-
eral, it was observed that the levels of E-specific IgG in sera 
rapidly decreased when VV-E was used as immunogen of pri-
mary vaccination. Furthermore, priming with VV-E and boost-
ing with rAd-E led to production of E-specific IgG1 isotype 
with higher levels than the other group, when the levels of 
E-specific  IgG  isotypes,  IgG1  and  IgG2a,  were  determined 
(Fig. 4B and C). Notably, if VV-E was used for primary vacci-
nation, the levels of E-specific IgG1 isotype were maintained 
till  14  days  post-boosting,  but  E-specific  IgG2a  levels 
decreased. Therefore, these results suggest that E-specific IgG 
and its isotypes, IgG1 and IgG2a, may be produced at various 
levels  by  alternating  prime-boost  immunization  using  DNA Immunity Induced by Alternating Prime-boost Vaccination against DenV2
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Figure 3. CD8＋ T cell responses specific for E protein of DenV 
following immunization with plasmid DNA and live viral vectors. (A)
In vivo CTL killing activity. Groups of mice were immunized with
plasmid DNA (pDE), recombinant adenovirus (rAd-E), and vaccinia 
virus (VV-E) expressing E protein, and used for in vivo CTL killing 
activity 14 days later. (B) IFN-γ-producing CD8＋ T cells in response
to epitope peptide stimulation. Splenocytes prepared from immunized
mice were stimulated with E331-339 (SPCKIPFEI) epitope peptide for 8 
h and used for intracellular cytokine staining. Plasmid DNA empty 
vector (pCIneo), recombinant adenovirus expressing LacZ (rAd-LacZ), 
and vaccinia virus expressing OVA (VV-OVA) were used as the 
negative control. Data represent average and standard deviation 
derived from 4 mice per group. *p＜0.05; **p＜0.01 compared 
between the indicated groups.
Figure 4. Serum IgG and its isotypes specific for E protein of DenV
following alternating prime-boost immunization with plasmid DNA 
and live viral vectors. Groups of mice that received plasmid DNA (D),
recombinant adenovirus (A), or vaccinia virus (V) expressing E protein
of DenV were boosted with alternate vehicle 7 days post-immu-
nization. The levels of E-specific IgG (A), and its isotypes, IgG1 (B) 
and IgG2a (C), were determined by conventional ELISA 7 and 14 days
post-boosting. Data represent average and standard deviation derived
from 5 mice per group.
vaccine and live viral vector, depending on the properties of 
immunogens  used  for  primary  vaccination.
CD4＋ T cell responses induced by alternating prime- 
boost immunization using plasmid DNA and live viral 
vectors expressing E protein
When the production of Th1- and Th2-type cytokines by CD4＋ 
T  cells  stimulated  with  E  protein  was  analyzed,  the  results 
showed a different pattern from E-specific IgG (Fig. 5). The 
group of mice that received priming with rAd-E and boosting 
with  pDE  showed  a  higher  production  of  IL-2  and  IFN-γ 
from stimulated CD4＋ T cells (Fig. 5A and C). However, pri-
ming  with  VV-E  and  boosting  with  rAd-E  that  showed  the 
highest level of E-specific IgG induced lower production of 
IL-2  and  IFN-γ from  stimulated  CD4＋ T  cells.  IL-4  pro-
duction by CD4＋ T cells showed no pattern correlated with 
the  protocols  of  alternating  prime-boost  vaccination  using 
DNA  vaccine  and  live  viral  vectors  (Fig.  5B).  Furthermore, 
when E-specific CD4＋ T cells producing IFN-γ were enum-Immunity Induced by Alternating Prime-boost Vaccination against DenV2
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Figure 5. Th1- and Th2-type cytokine production from CD4＋ T cells
by stimulation with E protein of DenV following alternating 
prime-boost immunization with plasmid DNA and live viral vectors.
Groups of mice that received plasmid DNA (D), recombinant
adenovirus (A), or vaccinia virus (V) expressing E protein of DenV 
were boosted with alternate vehicle 7 days post-immunization. Two 
weeks after boosting, splenocytes prepared from were stimulated with
E protein-pulsed syngeneic APCs for 3 days. The levels of IL-2 (A),
IL-4 (B), and IFN-γ (C) in culture supernatants were determined by 
ELISA. Data represent average and standard deviation derived from 
5 mice per group. *p＜0.05; **p＜0.01; ***p＜0.001 compared 
between the indicated groups.
Figure 6. Enumeration of IFN-γ-producing CD4＋ T cells by E protein
stimulation. Two weeks after boosting, splenocytes prepared from im-
munized mice were stimulated with E protein-pulsed syngeneic APCs
for 12 h, and the percentages (A) and number (B) of IFN-γ-producing
CD4＋ T cells were determined by intracellular staining of IFN-γ and
CD154. Data represent average and standard deviation derived from 
4 mice per group. **p＜0.01; ***p＜0.001 compared between the
indicated groups.
erated by intracellular CD154 and IFN-γ staining (39,40), the 
results revealed that priming with rAd and boosting with pDE 
induced  the  highest  number  of  IFN-γ-producing  E-specific 
CD4＋ T cells than other immunization (Fig. 6A). Similarly, 
groups of mice that received priming with rAd-E and boosting 
with  VV-E  exhibited  a  higher  number  of  IFN-γ-producing 
E-specific CD4＋ T cells in spleen (Fig. 6B). Of particular in-
terest, priming with pDE showed inhibited CD4＋ T cell re-
sponses after boosting with either rAD-E or VV-E. Taken to-
gether, these results indicate that CD4＋ T cell responses ach-
ieved by priming with adenovirus expressing E protein and 
boosting with DNA vaccine were superior to other immuniza-
tion protocols, and primary responses induced by DNA vac-
cine may interfere with CD4＋ T cell responses of liver viral 
vector  as  booster.
CD8＋ T cell responses induced by alternating pri-
me-boost immunization using plasmid DNA and live 
viral vectors expressing E protein
When CD8＋ T cell responses specific for E protein of DenV2 
were determined by  in vivo CTL killing activity, the results 
revealed  that  priming  with  VV-E  and  boosting  with  pDE 
showed the most potent in vivo CTL killing activity (Fig. 7A). Immunity Induced by Alternating Prime-boost Vaccination against DenV2
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Figure 7. CD8＋ T cell responses specific for E protein of DenV 
following alternating prime-boost immunization with plasmid DNA 
and live viral vectors. (A) In vivo CTL killing activity. Groups of mice
that received plasmid DNA (D), recombinant adenovirus (A), or 
vaccinia virus (V) expressing E protein of DenV were boosted with 
an alternate vehicle 7 days post-immunization. In vivo CTL killing 
activity was determined 14 days post-boosting. (B and C) IFN-γ- 
producing CD8＋ T cells in response to epitope peptide stimulation.
Splenocytes prepared from mice immunized with alternating 
prime-boost vaccine vehicles were stimulated with E331-339 (SPC-
KIPFEI) epitope peptide for 8 h and used for intracellular cytokine 
staining. Data represent average and standard deviation derived from
4 mice per group. **p＜0.01; ***p＜0.001 compared between the 
indicated groups.
This exceeded the results achieved by priming and boosting 
with the same vaccine VV-E, and was superior to responses 
induced  by  priming  with  rAD-E  and  boosting  with  pDE. 
G r o u p s  o f  m i c e  t h a t  r e c e i v e d  p D E  a s  p r i m a r y  i m m u n o g e n  
showed  lower  in  vivo C T L  k i l l i n g  a c t i v i t y  t h a n  w i t h  o t h e r  
methods. Consistently, priming with VV-E and boosting with 
pDE  showed  a  higher  number  of  IFN-γ-producing  CD8＋ 
T  cells  in  response  to  stimulation  with  E331-339  (SPCKIPFEI) 
epitope peptide (Fig 7B and C). Also, the number of IFN-γ- 
producing CD8＋ T cells induced by primary immunization 
with pDE was not increased by boosting with live viral vec-
tors  including  rAd-E  and  VV-E.  These  results  indicate  that 
boosting with DN A vaccine expressing E protein of DenV2 
following primary immunization with live viral vectors elicits 
strong  CD8＋ T  cell  responses.
DISCUSSION
We demonstrate that DNA vaccine, adenovirus, and vaccinia 
virus expressing E protein of DenV2 induced differential im-
mune responses. Among three constructs, VV-E induced the 
most potent IgG responses, Th1-type cytokine production by 
stimulated CD4＋ T cells, and CD8＋ T cell response. rAd-E 
showed  higher  production  of  Th2-type  cytokine  IL-4  com-
pared  to other  constructs,  DNA  vaccine and vaccinia  virus. 
Furthermore, when such constructs were used for alternating 
prime-boost vaccination, the results revealed a different pat-
tern of immune responses, depending on the constructed vac-
cine used for the priming step. Notably, priming with VV-E 
induced higher E-specific IgG levels which rapidly decreased 
c o m p a r e d  t o  t h e  g r o u p  t h a t  r e c e i v e d  r A d - E  a s  a  p r i m i n g  
vaccine. Also, strong CD8＋ T cell responses specific for E 
protein were induced when VV-E was used for priming the 
vaccine vehicle, and such CD8＋ T cell responses were sig-
nificantly boosted with pDE vaccination, compared to booster 
vaccination  with  either  rAd-E  or  VV-E.  In  contrast,  priming 
with rAd-E induced stronger CD4＋ T cell responses which 
subsequently boosted DNA vaccination more than others, as 
determined  by  intracellular  CD154  and  IFN-γ  staining. 
Therefore, these results indicate that priming with live viral 
vector  vaccine  could  lead  to  a  different  pattern  of  E  pro-
tein-specific immune responses that were significantly more 
enhanced  by  booster  vaccination  with  DNA  vaccine,  com-
pared  to  live  viral  vector  vaccine.
    Vaccination protocols commonly require multiple immuni-
zations to achieve robust, protective, and sustained immune 
responses.  In  particular,  heterologous  prime-boost  vacci-
nation  with  DNA  vaccine  and  live  viral  vector  vaccine  has 
emerged  as  an  effective  strategy  for  eliciting  a  robust  re-
s p o n s e  t o  t a r g e t  a n t i g e n  ( 2 5 , 26).  In  such  vaccination  strat-
egies, the most effective approach has proven to be priming 
with DNA vaccine and boosting with recombinant viral vector 
expressing the same antigen (25,26). This approach has been 
used  extensively  in  the  development  of  vaccines  against  a Immunity Induced by Alternating Prime-boost Vaccination against DenV2
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number of pathogens including human immunodeficiency vi-
rus (HIV) (42,43), herpesvirus (44), hepatitis C virus (HCV) 
(30), Ebola virus (45), and highly pathogenic avian influenza 
virus (HPAI) H5N1 (46,47). However, this dogma has some-
times been challenged by different results which show that 
priming with either live viral vector or live attenuated vaccine 
and boosting with DNA vaccine showed stronger responses 
than priming with DNA vaccine and boosting with live viral 
vector (27,28). In addition, priming with live viral vector vac-
cine and boosting with DNA vaccine induced the most potent 
immune  responses  at  both  systemic  and  mucosal  sites  if 
prime-boost vaccination is applied to mucosal route (48). Our 
results support the later notion at least in prime-boost vacci-
nation against E protein of dengue virus type 2. Of particular 
interest, a  different  magnitude  of CD4＋ and CD8＋ T cell 
responses  were  induced  if  either  rAd-E  or  VV-E  is  used  as 
priming vaccine vector. Minutely, priming with rAd-E induced 
higher number of CD4＋ T cells specific for E protein follow-
ing  boosting  with  pDE,  whereas  stronger  CD8＋ T  cell  re-
sponses  were  induced  by  priming  with  VV-E  followed  by 
boosting with pDE. The reason that priming with viral vector 
vaccine and boosting with pDE showed effective immune re-
sponses may be explained by escape of DNA vaccine to inter-
ference conferred by pre-existing immunity (22,23,49). Con-
ceivably, it is possible that pre-existing immunity induced by 
priming  with  pDE  or  live  viral  vector  vaccine  (rAD-E  and 
VV-E) could inhibit immune responses provided by boosting 
with live viral vaccine expressing the same antigen, E protein. 
Indeed,  the  group  that  received  pDE  at  both  priming  and 
boosting  showed  stronger  CD4＋ responses  than  the  group 
that  received  priming  with  pDE  and  boosting  with  either 
rAD-E or VV-E (Fig. 6). However, how priming with either 
rAd-E or VV-E induced different patterns of CD4＋ and CD8＋ 
T cell responses following boosting with pDE remains to be 
explained.
    Alternating prime-boost immunization is known to confer 
synergistically stronger responses to antigens and greater pro-
tection than immunization with either vaccine alone (25,26). 
However, the immunological basis for this outcome remains 
to be resolved. It is likely that the success of this approach 
may depend on several factors. In some instances, immune 
responses to repeated administration of the vector used for 
the  primary  immunization  can  neutralize  the  immunity  in-
duced by a booster, thereby inhibiting the effective immune 
responses that follow boosting. Also, the prime-boost vacci-
nation may enable encoded antigen to be presented through 
alternative  modes,  depending  on  the  diversity  of  antigen 
delivery. In particular, boosting with live viral vector may se-
lectively  expand  the  small  population  of  antigen-specific 
CD4/CD8 T cells by inducing type I IFN production, leading 
to IL-15 production, which has been known to maintain CD8＋ 
T cell proliferation and survival (50,51). Moreover, adenovirus 
appears to infect early dendritic cells (DCs), which may differ-
entiate to mature DCs that present antigens more effectively 
(30,31). Adenovirus also synthesizes larger quantities of pro-
teins that are taken up by endocytosis. Similarly, vaccinia vi-
rus can replicate in several types of epithelial cells as well 
as  antigen-presenting  cells  to  provide  antigen  for  cognate 
lymphocytes.  In  the  present  study,  we  used  replication-in-
competent adenovirus that can provide antigen protein from 
infected cells, whereas vaccinia virus can replicate in some 
cells of immunocompromised hosts. Thus, it is possible that 
vaccinia virus could induce stronger responses compared to 
the adenovirus at equivalent antigen doses (Fig. 1). Also, the 
divergent  cell  targeting  and  antigen  presentation  of  ad-
enovirus  and  vaccinia  virus  complement  each  other  in 
prime-boost vaccination, allowing a greater outcome of im-
mune  responses  than  with  either  vaccine  vehicle  alone. 
    Optimal vaccination to provide protective immunity against 
dengue virus is still challenging. One of the major issues to 
develop  vaccines  against  dengue  infection  is  how  to  effec-
tively provide protective immunity against all four serotypes 
of the dengue virus. We hope that the alternating prime-boost 
vaccination using DNA vaccine, adenovirus, and vaccinia vi-
rus expressing E protein can be used as a effective prophy-
lactic strategy to control fatal DHF and DSS caused by dengue 
infection.  To  achieve  the  practical  development  of  vacci-
nation strategies against dengue virus, the prime-boost vacci-
nation using DNA vaccine and/or live viral vector vaccine ex-
pressing tetravalent antigen is recommended. Therefore, our 
observation will provide valuable information for the estab-
lishment of optimal prime-boost vaccination against dengue 
virus.
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